Prediction: BridgeBio Pharma Will Beat the Market. Here's Why
Explore the exciting world of BridgeBio Pharma (NASDAQ: BBIO) with our expert analysts in this Scoreboard episode. Check out the video below to gain valuable insights into market trends and potential ...
Hosted on MSN6h
BridgeBio Oncology to Go Public in SPAC Deal Bringing $450 Million-Plus for Trio of Cancer Drugs
Clinical-stage BridgeBio Oncology Therapeutics, whose financial backers include Cormorant Asset Management, is going public ...
The Pharma Letter14h
BridgeBio spin-out in SPAC deal to target RAS and PI3Kα malignancies
BridgeBio Oncology Therapeutics (BBOT), a company advancing small molecule therapeutics targeting RAS and PI3Ka malignancies, ...
Apellis Pharmaceuticals (APLS) Receives a Hold from Scotiabank
Scotiabank analyst Greg Harrison maintained a Hold rating on Apellis Pharmaceuticals (APLS – Research Report) today and set a price target of ...
Scotiabank Remains a Buy on Liquidia Technologies (LQDA)
Scotiabank analyst Greg Harrison maintained a Buy rating on Liquidia Technologies (LQDA – Research Report) today and set a price target of ...
BridgeBio Oncology and Helix enter definitive merger agreement
BridgeBio Oncology has entered a definitive merger agreement with Helix Acquisition Corp II, which will result in the ...